Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases : a multicentric matched cohort study
© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ..
OBJECTIVES: The impact of inflammatory rheumatic diseases on COVID-19 severity is poorly known. Here, we compare the outcomes of a cohort of patients with rheumatic diseases with a matched control cohort to identify potential risk factors for severe illness.
METHODS: In this comparative cohort study, we identified hospital PCR+COVID-19 rheumatic patients with chronic inflammatory arthritis (IA) or connective tissue diseases (CTDs). Non-rheumatic controls were randomly sampled 1:1 and matched by age, sex and PCR date. The main outcome was severe COVID-19, defined as death, invasive ventilation, intensive care unit admission or serious complications. We assessed the association between the outcome and the potential prognostic variables, adjusted by COVID-19 treatment, using logistic regression.
RESULTS: The cohorts were composed of 456 rheumatic and non-rheumatic patients, in equal numbers. Mean age was 63 (IQR 53-78) years and male sex 41% in both cohorts. Rheumatic diseases were IA (60%) and CTD (40%). Most patients (74%) had been hospitalised, and the risk of severe COVID-19 was 31.6% in the rheumatic and 28.1% in the non-rheumatic cohort. Ageing, male sex and previous comorbidity (obesity, diabetes, hypertension, cardiovascular or lung disease) increased the risk in the rheumatic cohort by bivariate analysis. In logistic regression analysis, independent factors associated with severe COVID-19 were increased age (OR 4.83; 95% CI 2.78 to 8.36), male sex (1.93; CI 1.21 to 3.07) and having a CTD (OR 1.82; CI 1.00 to 3.30).
CONCLUSION: In hospitalised patients with chronic inflammatory rheumatic diseases, having a CTD but not IA nor previous immunosuppressive therapies was associated with severe COVID-19.
| Errataetall: |
CommentIn: Rheumatol Int. 2021 Jun;41(6):1097-1103. - PMID 33856543 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:79 |
|---|---|
| Enthalten in: |
Annals of the rheumatic diseases - 79(2020), 12 vom: 16. Dez., Seite 1544-1549 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Pablos, Jose L [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 26.11.2020 Date Revised 29.08.2023 published: Print-Electronic CommentIn: Rheumatol Int. 2021 Jun;41(6):1097-1103. - PMID 33856543 Citation Status MEDLINE |
|---|
| doi: |
10.1136/annrheumdis-2020-218296 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM313707057 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM313707057 | ||
| 003 | DE-627 | ||
| 005 | 20231225151141.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/annrheumdis-2020-218296 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1045.xml |
| 035 | |a (DE-627)NLM313707057 | ||
| 035 | |a (NLM)32796045 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Pablos, Jose L |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases |b a multicentric matched cohort study |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.11.2020 | ||
| 500 | |a Date Revised 29.08.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Rheumatol Int. 2021 Jun;41(6):1097-1103. - PMID 33856543 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ. | ||
| 520 | |a OBJECTIVES: The impact of inflammatory rheumatic diseases on COVID-19 severity is poorly known. Here, we compare the outcomes of a cohort of patients with rheumatic diseases with a matched control cohort to identify potential risk factors for severe illness | ||
| 520 | |a METHODS: In this comparative cohort study, we identified hospital PCR+COVID-19 rheumatic patients with chronic inflammatory arthritis (IA) or connective tissue diseases (CTDs). Non-rheumatic controls were randomly sampled 1:1 and matched by age, sex and PCR date. The main outcome was severe COVID-19, defined as death, invasive ventilation, intensive care unit admission or serious complications. We assessed the association between the outcome and the potential prognostic variables, adjusted by COVID-19 treatment, using logistic regression | ||
| 520 | |a RESULTS: The cohorts were composed of 456 rheumatic and non-rheumatic patients, in equal numbers. Mean age was 63 (IQR 53-78) years and male sex 41% in both cohorts. Rheumatic diseases were IA (60%) and CTD (40%). Most patients (74%) had been hospitalised, and the risk of severe COVID-19 was 31.6% in the rheumatic and 28.1% in the non-rheumatic cohort. Ageing, male sex and previous comorbidity (obesity, diabetes, hypertension, cardiovascular or lung disease) increased the risk in the rheumatic cohort by bivariate analysis. In logistic regression analysis, independent factors associated with severe COVID-19 were increased age (OR 4.83; 95% CI 2.78 to 8.36), male sex (1.93; CI 1.21 to 3.07) and having a CTD (OR 1.82; CI 1.00 to 3.30) | ||
| 520 | |a CONCLUSION: In hospitalised patients with chronic inflammatory rheumatic diseases, having a CTD but not IA nor previous immunosuppressive therapies was associated with severe COVID-19 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a ankylosing | |
| 650 | 4 | |a arthritis | |
| 650 | 4 | |a autoimmune diseases | |
| 650 | 4 | |a epidemiology | |
| 650 | 4 | |a psoriatic | |
| 650 | 4 | |a rheumatoid | |
| 650 | 4 | |a spondylitis | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Drug Combinations |2 NLM | |
| 650 | 7 | |a Glucocorticoids |2 NLM | |
| 650 | 7 | |a Immunosuppressive Agents |2 NLM | |
| 650 | 7 | |a lopinavir-ritonavir drug combination |2 NLM | |
| 650 | 7 | |a Lopinavir |2 NLM | |
| 650 | 7 | |a 2494G1JF75 |2 NLM | |
| 650 | 7 | |a remdesivir |2 NLM | |
| 650 | 7 | |a 3QKI37EEHE |2 NLM | |
| 650 | 7 | |a Adenosine Monophosphate |2 NLM | |
| 650 | 7 | |a 415SHH325A |2 NLM | |
| 650 | 7 | |a Hydroxychloroquine |2 NLM | |
| 650 | 7 | |a 4QWG6N8QKH |2 NLM | |
| 650 | 7 | |a Ritonavir |2 NLM | |
| 650 | 7 | |a O3J8G9O825 |2 NLM | |
| 650 | 7 | |a Alanine |2 NLM | |
| 650 | 7 | |a OF5P57N2ZX |2 NLM | |
| 700 | 1 | |a Galindo, María |e verfasserin |4 aut | |
| 700 | 1 | |a Carmona, Loreto |e verfasserin |4 aut | |
| 700 | 1 | |a Lledó, Ana |e verfasserin |4 aut | |
| 700 | 1 | |a Retuerto, Miriam |e verfasserin |4 aut | |
| 700 | 1 | |a Blanco, Ricardo |e verfasserin |4 aut | |
| 700 | 1 | |a Gonzalez-Gay, Miguel A |e verfasserin |4 aut | |
| 700 | 1 | |a Martinez-Lopez, David |e verfasserin |4 aut | |
| 700 | 1 | |a Castrejón, Isabel |e verfasserin |4 aut | |
| 700 | 1 | |a Alvaro-Gracia, José M |e verfasserin |4 aut | |
| 700 | 1 | |a Fernández Fernández, David |e verfasserin |4 aut | |
| 700 | 1 | |a Mera-Varela, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Manrique-Arija, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Mena Vázquez, Natalia |e verfasserin |4 aut | |
| 700 | 1 | |a Fernandez-Nebro, Antonio |e verfasserin |4 aut | |
| 700 | 0 | |a RIER Investigators Group |e verfasserin |4 aut | |
| 700 | 0 | |a RIER investigators group |e verfasserin |4 aut | |
| 700 | 1 | |a Aguirre, Rodrigo |e investigator |4 oth | |
| 700 | 1 | |a Seijas-López, Álvaro |e investigator |4 oth | |
| 700 | 1 | |a Blanco, Francisco J |e investigator |4 oth | |
| 700 | 1 | |a Carreira, Patricia |e investigator |4 oth | |
| 700 | 1 | |a Martín-López, María |e investigator |4 oth | |
| 700 | 1 | |a Gonzalez, Antonio |e investigator |4 oth | |
| 700 | 1 | |a Puig-Kröger, Amaya |e investigator |4 oth | |
| 700 | 1 | |a Salas, Luis |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of the rheumatic diseases |d 1939 |g 79(2020), 12 vom: 16. Dez., Seite 1544-1549 |w (DE-627)NLM000174114 |x 1468-2060 |7 nnns |
| 773 | 1 | 8 | |g volume:79 |g year:2020 |g number:12 |g day:16 |g month:12 |g pages:1544-1549 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1136/annrheumdis-2020-218296 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 79 |j 2020 |e 12 |b 16 |c 12 |h 1544-1549 | ||